Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.38 |
| ▸ | CTSS | P25774 | 10/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28655193 | 1.00 | CTSK (0.38) | CTSKCTSSMEN1KMT2ACTSL | |
| SCHEMBL27504700 | 0.80 | TDP1 (0.41) | MEN1KMT2AGAACYP2D6 | |
| SCHEMBL5052844 | 0.79 | KMT2A (0.34) | MEN1KMT2AGAACYP2D6 | |
| SCHEMBL28744759 | 0.79 | KMT2A (0.34) | MEN1KMT2AGAACYP2D6 | |
| SCHEMBL1259908 | 0.79 | CTSK (0.38) | CTSKCTSSMEN1KMT2ACTSL | |
| SCHEMBL27416647 | 0.77 | MEN1 (0.36) | CTSKMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL547994 | 0.76 | CTSK (0.38) | CTSKCTSSMEN1KMT2ACTSL | |
| SCHEMBL1258946 | 0.75 | MEN1 (0.34) | CTSKCTSSMEN1KMT2ACTSL | |
| SCHEMBL14688156 | 0.75 | MEN1 (0.34) | CTSKCTSSMEN1KMT2ACTSL | |
| SCHEMBL28548719 | 0.74 | SLC1A2 (0.41) | MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021057014-A1 | KLUYVEROMYCES MARXIANUS ALDO-KETO REDUCTASE KMAKR MUTANT AND APPLICATION THEREOF | 浙江工业大学 | 2021-04-01 | — | — | WO | claimed |
| CN-112899246-B | Aldehyde ketone reductase KmAKR mutant and application thereof in catalytic synthesis of chiral alcohol | 浙江工业大学 | 2022-06-21 | — | — | CN | disclosed |
| CN-111778223-B | Method for modifying stereoselectivity of carbonyl reductase, carbonyl reductase mutant and application | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-110577940-B | Kluyveromyces marxianus aldehyde ketone reductase KmAKR mutant and application thereof | 浙江工业大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-112899246-A | Aldehyde ketone reductase KmAKR mutant and application thereof in catalytic synthesis of chiral alcohol | 浙江工业大学 | 2021-06-04 | — | — | CN | disclosed |
| CN-109055327-B | Aldehyde ketone reductase mutant and application thereof | 浙江工业大学 | 2021-04-06 | — | — | CN | disclosed |
| WO-2021057014-A1 | KLUYVEROMYCES MARXIANUS ALDO-KETO REDUCTASE KMAKR MUTANT AND APPLICATION THEREOF | 浙江工业大学 | 2021-04-01 | — | — | WO | disclosed |
| CN-110004120-B | Recombinant aldone reductase mutant and application thereof | 浙江工业大学 | 2021-02-02 | — | — | CN | disclosed |
| CN-111778223-A | Method for modifying stereoselectivity of carbonyl reductase, carbonyl reductase mutant and application | 浙江工业大学 | 2020-10-16 | — | — | CN | disclosed |
| CN-107058248-B | Recombinant aldone reductase mutant, gene, vector, engineering bacterium and application thereof | 浙江工业大学 | 2020-10-09 | — | — | CN | disclosed |
| CN-106929521-B | Aldehyde ketone reductase gene recombination co-expression vector, engineering bacterium and application thereof | 浙江工业大学 | 2020-08-21 | — | — | CN | disclosed |
| CN-110577940-A | Kluyveromyces marxianus aldehyde ketone reductase KmAKR mutant and application thereof | 浙江工业大学 | 2019-12-17 | — | — | CN | disclosed |
| CN-105671010-A | Aldehyde ketone reductase mutant, gene, engineering bacterium and application of mutant | 浙江工业大学 | 2016-06-15 | — | — | CN | disclosed |
| CN-104630242-A | Carbonyl reductase gene, codase, vector, engineering bacterium and application thereof | UNIV ZHEJIANG TECHNOLOGY | 2015-05-20 | — | — | CN | disclosed |
| EP-2066788-B1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | CODEXIS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8617864-B2 | Polynucleotides encoding ketoreductases for producing stereoisomerically pure statins and synthetic intermediates therefor | CODEXIS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130040364-A1 | POLYNUCLEOTIDES ENCODING KETOREDUCTASES FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | CODEXIS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2066788-A2 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | Codexis, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080248539-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | CODEXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008042876-A2 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | CODEXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080248539-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR | COASY, FAR1, HMGCR | CTSK 3212/4885CTSS 2003/4885MEN1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.